Circulating Cell-Free Tumor DNA Market

Circulating Cell-Free Tumor DNA Market, by Tumor Type (Malignant Tumors, Precancerous Tumors), by Cancer Type (Lung Cancer, Colorectal Cancer, Breast Cancer, Others) by Technology (PCR, Massively Parallel Sequencing, Single Nucleotide Polymorphism), by Application (Cancer Diagnosis, Targeting Therapeutics, Prognosis Indication), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

The term circulating tumor DNA (ctDNA) refers to DNA from malignant cells and tumors that circulate in the bloodstream. The nucleus of a cell contains most of the DNA. Cells die and are replaced by new ones as a tumor expands. The broken-down dead cells discharge their contents, including DNA, into the bloodstream. ctDNA are short segments of DNA that are typically less than 200 nucleotides in length. The amount of ctDNA varies from person to person and is influenced by the type of tumor, its location, and, in the case of malignant tumors, the stage of the disease. Circulating tumor DNA (ctDNA) usually contains genetic changes that could be useful for detecting cancer. Other significant uses of ctDNA include prognosis, therapeutic monitoring, and tumor volume estimation. When new cancer detection tests can spot cancer in its earliest, asymptomatic stage, when cure rates are highest, they have the greatest clinical utility. Circulating tumor DNA analysis can help in the early detection of cancer and is also used in providing molecular targeting therapeutics.

Market Dynamics

Increasing adoption of organic growth strategies, such as product launches by key players in the market to expand their product portfolio, is expected to drive market growth over the forecast period. For instance, in July 2022, BillionToOne Inc., a next-generation molecular diagnostics company, announced the launch of its first oncology liquid biopsy products, Northstar Select and Northstar Response. The products are currently available for research use with select academic cancer centers. Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel. Leveraging BillionToOne’s proprietary molecular counting technology, or Quantitative Counting Templates (QCTs), the panel achieves a notable limit of detection for the identification of actionable alterations. Meanwhile, Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay.

Key features of the study:

This report provides an in-depth analysis of the global circulating cell-free tumor DNA market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global circulating cell-free tumor DNA market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.

Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global circulating cell-free tumor DNA analysis report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global circulating cell-free tumor DNA market

Detailed Segmentation:

Global Circulating Cell-Free Tumor DNA Market, By Tumor Type:

Malignant Tumors

Precancerous Tumors

Global Circulating Cell-Free Tumor DNA Market, By Cancer Type:

Lung Cancer

Colorectal Cancer

Breast Cancer

Others

Global Circulating Cell-Free Tumor DNA Market, By Technology:

PCR

Massively Parallel Sequencing

Single Nucleotide Polymorphism

Global Circulating Cell-Free Tumor DNA Market, By Application:

Cancer Diagnosis

Targeting Therapeutics

Prognosis Indication

Global Circulating Cell-Free Tumor DNA Market, By Region:

North America

By Country:

U.S.

Canada

Latin America

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Country

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Country:

GCC

Israel

Rest of Middle East

Africa

By Country/Region:

South Africa

Central Africa

North Africa

Company Profiles

Biocept, Inc.*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

Illumina, Inc.

Quest Diagnostics Incorporated

KURABO INDUSTRIES LTD

PerkinElmer chemagen Technologie GmbH

Biodesix

Guardant Health

QIAGEN

Sequenom, Inc.

Agilent Technologies, Inc.

Fluxion Biosciences Inc.

Natera, Inc.

Agena Bioscience, Inc.

Paragon Genomics, Inc.

Lucence Health Inc.

Eurofins Genomics

Thermo Fisher Scientific

“*” marked represents similar segmentation in other categories in the respective section.